BLOOM — Bariatric Lymphedema One-Stage Operative Management
BLOOM is a reported combination of sleeve gastrectomy and vascularized gastroepiploic lymph node transfer (VLNT). The 2025 report describes one woman with obesity and secondary lower-limb lymphedema. It provides an early feasibility observation, without establishing a standard indication or a benefit over staged treatment.[1]
Its direct evidence concerns a limb, rather than a genital reconstruction. For established assessment and treatment principles, see Genital Lymphedema, Complex Decongestive Therapy, and Vascularized Lymph Node Transfer.
Reported concept and donor anatomy
The index patient was 44 years old, with a BMI of 35 and secondary lower-limb lymphedema. The authors reported improvement after simultaneous bariatric surgery and VLNT. The publisher's supplementary-video description identifies the harvested nodes as left gastroepiploic. Right gastroepiploic artery dimensions and station-4d node maps from other donor studies should not be presented as the anatomy of this operation.[1]
If the two procedures are considered together, flap design, pedicle preservation, recipient vessels and ischemia management require advance coordination between the bariatric and reconstructive teams. A usable vascularized flap cannot be assumed to remain in an otherwise routinely divided gastric specimen. Shared access does not establish zero additional dissection, donor morbidity or perioperative risk.[1][2]
Obesity management remains important
Obesity can contribute to lymphatic dysfunction and complicate swelling control. Weight management is part of treatment, but established lymphatic damage and fibrosis may persist after weight loss. Animal evidence for improved pumping or inflammation should not be presented as proof that bariatric surgery restores normal human lymphatic function.[3]
The WISER Survivor randomized trial assigned 351 women with breast cancer-related arm lymphedema to weight loss, home exercise, both, or control care. At 12 months, weight loss did not improve the primary interlimb-volume difference. All groups received lymphedema care. This finding neither tests BLOOM nor determines whether obesity-related leg or genital disease benefits from a particular operation.[4]
Selection and counseling
Each component needs an independent clinical indication. BMI, ISL stage or a history of pelvic cancer treatment does not by itself establish a BLOOM indication. Assess the cause of swelling, fibrosis, remaining lymphatic pathways, conservative-treatment response, bariatric eligibility, nutritional status, previous abdominal surgery and the patient's priorities with the relevant specialists.[2][3]
Discuss the alternatives: continued conservative and obesity treatment, separate operations when indicated, lymphatic bypass where suitable collectors remain, and excision or liposuction for selected solid tissue burden. A combined operation may avoid a second anesthetic, but comparative complication rates, total recovery burden and long-term benefit remain unproven.[1][2]
An intra-abdominal donor avoids harvesting nodes from a limb-draining basin, but it introduces its own abdominal, vascular and flap risks. Published donor series do not establish a universally superior VLNT donor. Reductions in observed cellulitis episodes are clinical outcomes, not proof of complete immune restoration.[2]
Outcomes to document
Record weight change separately from limb volume or circumference, symptoms and quality of life, cellulitis episodes, compression needs, subsequent procedures, recipient and donor complications, and duration of follow-up. Without a comparative design, improvement after combined treatment cannot be apportioned to weight loss, node transfer or other interventions.[2][4]
References
1. Sim NH, Ong LW, Yeo MSW, Yeung BP, Wong AW. Bariatric Lymphedema One-Stage Operative Management (BLOOM). Obes Surg. 2025;35(5):1860–1863. doi:10.1007/s11695-025-07847-z. Publisher page and supplementary-video description.
2. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2023 consensus document. Lymphology. 2023;56:133–151. Full consensus.
3. Sudduth CL, Greene AK. Lymphedema and obesity. Cold Spring Harb Perspect Med. 2022;12(5):a041176. doi:10.1101/cshperspect.a041176
4. Schmitz KH, Troxel AB, Dean LT, et al. Effect of home-based exercise and weight loss programs on breast cancer-related lymphedema outcomes among overweight breast cancer survivors: the WISER Survivor randomized clinical trial. JAMA Oncol. 2019;5(11):1605–1613. doi:10.1001/jamaoncol.2019.2109